Navigation Links
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners
Date:7/11/2011

WARREN, N.J., July 11, 2011 /PRNewswire/ -- MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm® technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland ("APR"), announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.  The Company made the strategic decision to reacquire the commercial rights to Zuplenz from Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical, Inc. (NYSE: PRX), who had been marketing the product as part of an exclusive licensing agreement since its commercial launch in October 2010.  The New Drug Application (NDA) for Zuplenz will remain current and commercial availability will not be disrupted.

Zuplenz is a unique film formulation delivering either 4 or 8 mgs of ondansetron and was developed using MonoSol Rx's proprietary PharmFilm technology.  It is indicated for the prevention of postoperative nausea and vomiting (PONV), highly and moderately emetogenic cancer chemotherapy-induced nausea and vomiting (CINV), and radiotherapy-induced nausea and vomiting (RINV).  Zuplenz is poised to capture a broad share of this market, which generated $1.9 billion in 2010.

"Zuplenz provides patients suffering from nausea and vomiting as a result of chemotherapy or surgery with a minimally invasive and highly tolerable drug delivery form," said A. Mark Schobel, Chief Technology Officer and CEO, MonoSol Rx.  "We believe Zuplenz has the potential to improve the quality of life for many cancer patients in need of better supportive care and offers an important new dosage form for improving postoperative care for both inpatient and outpatient surgeries.  We look forward to maximizing this potential with a pharmaceutical partner that can effectively detail to physicians in the sizable U.S. market."

About MonoSol Rx

MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver drugs in films.  PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs.  The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized prescription and over-the-counter (OTC) drug products, a pipeline of prescription formulations based on PharmFilm® technology, and two recent FDA approvals - Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first combination sublingual film product for the treatment of opioid dependence.

MonoSol Rx's commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing.  For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration.  PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).  For press releases and other company information visit www.monosolrx.com.

About APR Applied Pharma Research s.a.

APR Applied Pharma Research s.a. is an independent, international and integrated Healthcare Company headquartered in Switzerland with a subsidiary in Charlotte (NC, USA) and focused on three major areas: Delivering, Funding and Supporting Innovation in Healthcare. In particular, APR develops and licenses innovative, value added and patented healthcare products and proprietary drug delivery systems primarily in the oral and topical fields; APR also invests in companies or early stage innovative projects and provides a balanced mix of equity funding and/or financing together with APR's development, scientific, technical, marketing, licensing and management skills and know how; finally, APR supports biotech and pharmaceutical companies in the development of new pharmaceutical projects by providing on a contract basis added value, consultancy and R&D services under contract using a General Contractor approach.

APR has entered into licensing and partnership agreements with pharmaceutical companies in over 100 countries worldwide with international sales on a worldwide basis.

For press releases and other company information visit www.apr.ch.

Contacts:

MonoSol Rx:
Dan Barber, Vice President, Business Development and Alliance Management
(732) 564-5000
dbarber@monosolrx.com

The Ruth Group (on behalf of MonoSol Rx)
Eric Reiss (media)
(646) 536-7032
ereiss@theruthgroup.com

Joshua Drumm (investors)
(646) 536-7006
jdrumm@theruthgroup.com

APR Applied Pharma Research s.a:
Paolo Galfetti, Chief Executive Officer
+41 91 6957020
paolo.galfetti@apr.ch


'/>"/>
SOURCE MonoSol Rx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
2. MonoSol Rx Issued Strategic US Patent Governing the Production of Pharmaceutical Films Containing Specific Drugs and Drug Classes
3. MonoSol Rx Secures 505(b)(2) Regulatory Pathway for Montelukast Sodium Oral Soluble Film
4. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
5. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
6. MonoSol Rx Issued Strategic U.S. Patent Governing the Manufacturing of Pharmaceutical Films
7. MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
10. Stryker Announces Exclusive Collaboration With RegenLab
11. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):